Translational medicine & biomarker strategy
Correlative Science Catalysts is an independent practice built on twenty years of translational science leadership in immunology, oncology, and cell therapy. I help biotech teams turn biomarker data into two things at once: faster, better-informed development decisions, and the evidence that supports a credible product narrative for regulators, investors, and partners.
20+ yrs
in translational medicine, from bench to registrational trials
15+
cell therapy, biologics and small molecule translational medicine programs led through all phases of development
$500M+
in partnerships and spinouts supported by high impact data
Accelerate the program
High-impact biomarker data sharpens patient selection, speeds up go/no-go calls, and gives dose-selection decisions a foundation that holds up as a program moves from Phase 1 toward registration.
Support the narrative
The same biomarker findings become the evidence a program needs — for an FDA meeting, a licensing discussion, or an investor deciding whether the mechanism is real. I help translate the data into that story.
Three decades of building scientific and translational medicine knowledge and capability in premier academic and biopharma settings
A practice built around three questions every program eventually has to answer.
Biomarker and translational medicine strategy, from indication selection through target product profile.
Hands-on program leadership for clinical biomarker work, from Phase 1 through registrational trials.
CRO and academic partnerships, CDx partner selection, and the internal team to hold it all together.
$300M
Translational data package behind Allogene's spinout from Pfizer
$45M
GSK collaboration on a NY-ESO TCR T cell program
200+
Patients screened under a companion diagnostic strategy built from scratch
3rd
Employee at a cell therapy company that grew past 300
